About

About Iktos Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in-silico, optimized to meet all key success criteria of a discovery project. Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery. With over 60 successful projects to date, Iktos supports its clients through software and strategic drug discovery collaborations. Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform. In January 2026, Iktos signed its largest Drug Discovery collaboration to date with Servier, for a total potential deal value of over €1 billion euros. For more information, visit Iktos.ai.